ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Redox-Responsive Polymeric Nanocapsules for Enhanced Tumor-Targeted Delivery of Antimicrobial Peptides.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anticancer Potential of Antimicrobial Peptides: Mechanisms, Clinical Application, Challenges, and Future Prospects.Drug development research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) hold promise as anticancer agents but suffer from proteolytic instability, systemic toxicity, and hemolysis. Here, we report a modular redox-responsive polymeric nanocapsule platform for enhanced tumor-targeted AMP delivery. Using melittin (MEL) as a stringent model, disulfide-crosslinked nanocapsules (nMEL) remain stable and inert under physiological conditions (<5% hemolysis) yet undergo glutathione-triggered shell cleavage in the tumor microenvironment to reactivate lytic activity via controlled MEL liberation. nMEL exhibits ∼4-fold higher tumor accumulation and suppresses subcutaneous tumor growth by ∼80% compared with free MEL. Incorporating phenylboronic acid ligands yields nMEL-PBA, which actively targets hypersalivated tumor cells, achieving 4.5-fold greater pulmonary enrichment and extending median survival to 43 days in a lung metastasis model. This strategy integrates systemic stability, tumor selectivity, and microenvironment-responsive activation, providing a generalizable approach to overcome long-standing barriers in AMP-based cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.